Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQB2102 combined with immunotherapy with or without chemotherapy in unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma
CTR20243929Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in gastroesophageal junction adenocarcinoma, sponsored by Nanjing Shunxin Pharmaceutical. Started Nov 2024; status: active.
02
Drugs
TQB2102
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20243929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243929.